From Medscape HIV/AIDS

Conference on Retroviruses and Opportunistic Infections (CROI) 2016

February 22 - 25, 2016; Boston, Massachusetts

February 22 - 25, 2016 Boston, Massachusetts

CROI Injectable HIV Prevention Drug Well Tolerated in Early Study Long-acting cabotegravir, developed to increase adherence, is a safe and effective pre-exposure prophylaxis for men at low risk for HIV, but most reported injection-site pain.
Medscape Medical News, February 25, 2016
CROI Risk for HIV Infection in US Dips, but Racial Gap Still Wide For black males, the risk is one in 20; for white males, it is one in 132. And even with early treatment, life expectancy is nearly a decade less for those who have the virus.
Medscape Medical News, February 24, 2016
CROI Monthly Vaginal Ring Moderately Reduces HIV Risk A vaginal ring inserted monthly helps prevent HIV transmission, two phase 3 sister studies of African women have shown.
Medscape Medical News, February 22, 2016